Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.
| Revenue (TTM) | $2.58B |
| Gross Profit (TTM) | $1.79B |
| EBITDA | $-10.18M |
| Operating Margin | -12.80% |
| Return on Equity | -32.00% |
| Return on Assets | -2.21% |
| Revenue/Share (TTM) | $11.29 |
| Book Value | $1.39 |
| Price-to-Book | 20.60 |
| Price-to-Sales (TTM) | 2.48 |
| EV/Revenue | 2.863 |
| EV/EBITDA | 205.86 |
| Quarterly Earnings Growth (YoY) | -17.40% |
| Quarterly Revenue Growth (YoY) | 38.20% |
| Shares Outstanding | $224.94M |
| Float | $212.46M |
| % Insiders | 5.46% |
| % Institutions | 71.55% |
Volatility is currently contracting
Hims & Hers Health (HIMS) is rated a buy at current levels, driven by robust international expansion and product innovation. International revenue surged over 17-fold YoY to $131M, with Eucalyptus acquisition and new markets fueling growth and future $600M+ 2026 target. AI investment aims to reduce customer-support costs and improve retention, with payback expected in 12–18 months as in-house capabilities scale.
Philadelphia, Pennsylvania--(Newsfile Corp. - August 19, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into the Board of Directors of Hims & Hers Health, Inc. (NYSE: HIMS) ("Hims & Hers" or the "Company") for potential breaches of fiduciary duties owed to the Company and its shareholders. The investigation is focused on whether the Company improperly shared private user health data with advertisers, engaged in deceptive billing practices, and made subscription cancellations unnecessarily difficult.
This disposition of 47,702 shares was executed at $28.15 per share for a total transaction value of $1.3 million. This activity was non-discretionary, as shares were withheld to satisfy tax liabilities associated with the quarterly vesting of restricted stock units.
The disposition involved 10,201 shares for an estimated value of $287,000 on the August 14 transaction date. The transaction was entirely direct, leaving the officer with 197,847 shares in direct ownership.
RADNOR, Pa., Aug. 18, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased or acquired Hims & Hers Health, Inc. securities and experienced significant financial losses.
In an exclusive interview, Hims & Hers CEO Andrew Dudum sits down with Squawk Box Co-Anchor Andrew Ross Sorkin and shares his perspective on how AI can transform healthcare, the company's transition from compound to brand name GLP-1s, and his vision to bring down the cost of healthcare.
Hims & Hers CEO Andrew Dudum defended the company against against an FTC lawsuit over its data sharing and subscription practices. In an interview with CNBC, he also said the company's sale of compounded GLP-1 drugs helped to bring prices for the treatments down.
RADNOR, Pa., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased or acquired Hims & Hers Health, Inc. securities and experienced significant financial losses.
New York, New York--(Newsfile Corp. - August 17, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Hims & Hers investor and have suffered losses, or if you have information that could assist in the Hims & Hers investigation, you may CLICK HERE to contact us.
New York, New York--(Newsfile Corp. - August 14, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Hims & Hers investor and have suffered losses, or if you have information that could assist in the Hims & Hers investigation, you may CLICK HERE to contact us.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HIMS and any ticker you trade — then tracks every position and per-strategy win rate.
